RU2013144207A - Комбинированные вакцины с пониженными дозами антигена и/или адъюванта - Google Patents
Комбинированные вакцины с пониженными дозами антигена и/или адъюванта Download PDFInfo
- Publication number
- RU2013144207A RU2013144207A RU2013144207/15A RU2013144207A RU2013144207A RU 2013144207 A RU2013144207 A RU 2013144207A RU 2013144207/15 A RU2013144207/15 A RU 2013144207/15A RU 2013144207 A RU2013144207 A RU 2013144207A RU 2013144207 A RU2013144207 A RU 2013144207A
- Authority
- RU
- Russia
- Prior art keywords
- adjuvant
- toxoid
- composition
- composition according
- iii
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims abstract 30
- 239000000427 antigen Substances 0.000 title claims abstract 13
- 102000036639 antigens Human genes 0.000 title claims abstract 13
- 108091007433 antigens Proteins 0.000 title claims abstract 13
- 229960005486 vaccine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 47
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims abstract 21
- 201000005702 Pertussis Diseases 0.000 claims abstract 15
- 229960003983 diphtheria toxoid Drugs 0.000 claims abstract 13
- 229960000814 tetanus toxoid Drugs 0.000 claims abstract 12
- 230000002163 immunogen Effects 0.000 claims abstract 11
- 239000000556 agonist Substances 0.000 claims abstract 10
- 241000991587 Enterovirus C Species 0.000 claims abstract 4
- 241000700721 Hepatitis B virus Species 0.000 claims abstract 3
- 102000002689 Toll-like receptor Human genes 0.000 claims 5
- 108020000411 Toll-like receptor Proteins 0.000 claims 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 241000709701 Human poliovirus 1 Species 0.000 claims 1
- 241000709704 Human poliovirus 2 Species 0.000 claims 1
- 241000709727 Human poliovirus 3 Species 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448226P | 2011-03-02 | 2011-03-02 | |
| US61/448,226 | 2011-03-02 | ||
| US201161565980P | 2011-12-01 | 2011-12-01 | |
| US61/565,980 | 2011-12-01 | ||
| PCT/IB2012/050989 WO2012117377A1 (en) | 2011-03-02 | 2012-03-02 | Combination vaccines with lower doses of antigen and/or adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013144207A true RU2013144207A (ru) | 2015-04-10 |
Family
ID=45852630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013144207/15A RU2013144207A (ru) | 2011-03-02 | 2012-03-02 | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20140112950A1 (enExample) |
| EP (1) | EP2680885B8 (enExample) |
| JP (2) | JP6191082B2 (enExample) |
| KR (1) | KR20140026392A (enExample) |
| CN (1) | CN103533954B (enExample) |
| AU (1) | AU2012222883A1 (enExample) |
| BR (1) | BR112013022397A2 (enExample) |
| CA (1) | CA2828844C (enExample) |
| ES (1) | ES2681698T3 (enExample) |
| RU (1) | RU2013144207A (enExample) |
| TR (1) | TR201811280T4 (enExample) |
| WO (1) | WO2012117377A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| BR112013005329A2 (pt) | 2010-09-10 | 2017-05-02 | Wyeth Llc | variantes não lipidadas de antígenos orf2086 de neisseria meningitidis |
| SI3590949T1 (sl) | 2010-10-01 | 2022-09-30 | Modernatx, Inc. | Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe |
| ES2681698T3 (es) | 2011-03-02 | 2018-09-14 | Glaxosmithkline Biologicals Sa | Vacunas de combinación con menores dosis de antígeno y/o adyuvante |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US20140363461A1 (en) * | 2011-09-01 | 2014-12-11 | Fabio Bagnoli | Adjuvanted formulations of staphylococcus aureus antigens |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| RU2649364C2 (ru) | 2011-12-16 | 2018-04-02 | Модерна Терапьютикс, Инк. | Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты |
| CN104519910B (zh) * | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
| US20150125486A1 (en) * | 2012-03-08 | 2015-05-07 | Novartis Ag | Adjuvanted formulations of pediatric antigens |
| AU2013229432A1 (en) | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| EP3520821A1 (en) | 2012-04-02 | 2019-08-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9526776B2 (en) | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
| MX363529B (es) * | 2012-09-18 | 2019-03-27 | Novartis Ag | Vesículas de membrana externa. |
| SI2922554T1 (sl) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminalno modificirana RNA |
| US9968673B2 (en) | 2013-02-26 | 2018-05-15 | Commissariat á l'ènergie atomique et aux ènergies alternatives | Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent |
| FR3002454B1 (fr) | 2013-02-26 | 2015-04-10 | Commissariat Energie Atomique | Composition immunogene sous forme d'emulsion |
| NZ630868A (en) | 2013-03-08 | 2017-02-24 | Janssen Vaccines & Prevention Bv | Acellular pertussis vaccine |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| BR112016004463A2 (pt) * | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| US10872313B2 (en) | 2015-06-02 | 2020-12-22 | ROCA Medical Ltd. | Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy |
| MA58292B1 (fr) | 2014-04-23 | 2025-01-31 | Modernatx, Inc. | Vaccins à base d'acide nucléique |
| CN104013955B (zh) * | 2014-06-18 | 2016-02-24 | 中国科学院过程工程研究所 | 一种不含表面活性剂的水包油乳液及其用途 |
| US10485862B2 (en) * | 2014-10-07 | 2019-11-26 | Serum Institute Of India Pvt Ltd | Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| JP2018511655A (ja) * | 2015-03-20 | 2018-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物 |
| US10548974B2 (en) * | 2015-06-02 | 2020-02-04 | ROCA Medical Ltd. | Therapeutic treatment kit for allergies based on DNA profiles |
| CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
| EA037283B1 (ru) * | 2015-09-16 | 2021-03-04 | ЭлДжи КЕМ, ЛТД. | Комбинированная вакцинная композиция для многократного дозирования |
| FR3043558B1 (fr) * | 2015-11-18 | 2017-12-29 | Commissariat Energie Atomique | Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant |
| WO2017085248A1 (fr) * | 2015-11-18 | 2017-05-26 | Commissariat à l'énergie atomique et aux énergies alternatives | Composition immunogène sous forme d'émulsion comprenant deux phases dispersées, l'une comprenant un antigène et l'autre comprenant un agent immunostimulant |
| IL299285B2 (en) | 2016-05-16 | 2024-12-01 | Access To Advanced Health Inst | Formulation containing tlr agonist and methods of use |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| CN106039301A (zh) * | 2016-06-30 | 2016-10-26 | 武汉博沃生物科技有限公司 | 肺炎球菌‑b型流感嗜血杆菌‑百白破联合疫苗的制备方法 |
| BR112019003419A2 (pt) * | 2016-08-26 | 2019-05-21 | Serum Institute Of India Private Limited | composição de vacina multivalente |
| AU2017321863B2 (en) * | 2016-09-02 | 2024-07-11 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| GB201807303D0 (en) | 2018-05-03 | 2018-06-20 | London School Of Hygeine & Tropical Medicine | Glyconjugate vaccines |
| JP7555929B2 (ja) * | 2018-12-24 | 2024-09-25 | 遠大賽威信生命科学（南京）有限公司 | Ｂ型肝炎を治療するための薬物製剤、その製造方法及び用途 |
| MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| CN111643661A (zh) * | 2020-06-08 | 2020-09-11 | 王竹林 | 新型免疫佐剂、化合物及其应用 |
| CN114917331B (zh) * | 2022-06-02 | 2025-03-28 | 金宇保灵生物药品有限公司 | 一种牛多杀性巴氏杆菌荚膜a型荚膜多糖疫苗及其制备方法 |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5204098A (en) | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5334379A (en) | 1989-07-14 | 1994-08-02 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| US5059258A (en) | 1989-08-23 | 1991-10-22 | Aluminum Company Of America | Phosphonic/phosphinic acid bonded to aluminum hydroxide layer |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| IL98715A0 (en) | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
| US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| WO1993018150A1 (en) | 1992-03-02 | 1993-09-16 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
| EP0658118B1 (en) | 1992-08-31 | 2002-01-23 | Baxter Healthcare S.A. | Vaccines against group c neisseria meningitidis |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| AU696941B2 (en) | 1994-07-01 | 1998-09-24 | Rican Limited | Helicobacter pylori antigenic protein preparation and immunoassays |
| ES2193205T3 (es) | 1994-11-24 | 2003-11-01 | Basilea Pharmaceutica Ag | Nuevas bencil pirimidinas. |
| DE69615362T3 (de) | 1995-06-07 | 2006-07-20 | Smithkline Beecham Biologicals S.A. | Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein |
| WO1997025429A1 (en) | 1996-01-04 | 1997-07-17 | Rican Limited | Helicobacter pylori bacterioferritin |
| GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP2261350A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| KR100682154B1 (ko) | 1998-05-07 | 2007-02-12 | 코릭사 코포레이션 | 아쥬번트 조성물 및 그의 사용방법 |
| CN1263510C (zh) | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 |
| AU1626199A (en) | 1998-12-04 | 2000-06-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vi-repa conjugate vaccine for immunization against salmonella typhi |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| MY125202A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| JP4948731B2 (ja) | 1999-12-02 | 2012-06-06 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 凍結乾燥の際に生物学的分子を安定化するための組成物および方法 |
| DE10012370A1 (de) | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| EP1297005B1 (en) | 2000-07-03 | 2009-08-26 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia pneumoniae |
| EP1355673B1 (en) | 2001-01-23 | 2012-05-30 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| WO2002091998A2 (en) | 2001-05-11 | 2002-11-21 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| JP2004532277A (ja) * | 2001-06-08 | 2004-10-21 | パウダージェクト ワクチンズ，インコーポレーテッド | 噴霧凍結乾燥組成物 |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| ES2312649T3 (es) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
| GB0202901D0 (en) | 2002-02-07 | 2002-03-27 | Glaxosmithkline Biolog Sa | Novel vaccine |
| BR0308768A (pt) | 2002-03-26 | 2005-02-15 | Chiron Srl | Sacarìdeos modificados possuindo estabilidade melhorada em água |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| JP2005533057A (ja) | 2002-06-13 | 2005-11-04 | ニューヨーク・ユニバーシティ | 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用 |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| US7818252B2 (en) | 2003-02-20 | 2010-10-19 | Gilat Satellite Networks, Ltd | Enforcement of network service level agreements |
| SI1644389T1 (sl) | 2003-06-16 | 2011-06-30 | Acad Of Science Czech Republic | Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi |
| AU2004251734B2 (en) | 2003-06-23 | 2010-11-04 | Baxalta GmbH | Vaccines against group Y neisseria meningitidis and meningococcal combinations thereof |
| JP4896715B2 (ja) | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物 |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| RU2006134631A (ru) | 2004-03-02 | 2008-04-10 | Чирон Корпорейшн (Us) | Иммуногенные композиции против chlamidia pneumoniae |
| GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| CA2560969A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| DK1742659T3 (da) | 2004-04-05 | 2013-06-03 | Zoetis P Llc | Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| DK1858920T3 (en) | 2005-02-18 | 2016-02-29 | Glaxosmithkline Biolog Sa | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI |
| WO2006137953A1 (en) | 2005-04-01 | 2006-12-28 | The Regents Of The Univerisity Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
| MX2007012337A (es) | 2005-04-08 | 2007-11-21 | Wyeth Corp | Separacion de contaminantes de polisacarido de streptococcus pneumoniae por manipulacion de ph. |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP2425856A1 (en) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| JP2008544745A (ja) | 2005-05-12 | 2008-12-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓのための免疫原性組成物 |
| WO2007000341A2 (en) | 2005-06-27 | 2007-01-04 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| EP1939198A4 (en) | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| US20090099216A1 (en) | 2005-09-22 | 2009-04-16 | Astrazeneca Aktiebolag A Corporation Of Sweden | Novel adenine compound |
| WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
| JPWO2007034817A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| AU2006310337B9 (en) | 2005-11-04 | 2013-11-28 | Novartis Ag | Adjuvanted influenza vaccines including cytokine-inducing agents |
| GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| HUE032903T2 (hu) * | 2005-12-22 | 2017-11-28 | Glaxosmithkline Biologicals Sa | Streptococcus pneumoniae kapszulárispoliszacharid-konjugátumok |
| CA2633142A1 (en) | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, S.R.L. | Chlamydial antigens |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| MX2008010611A (es) | 2006-02-17 | 2008-11-12 | Pfizer Ltd | Derivados de 3-desazapurina como moduladores de receptores similares a toll. |
| ES2388556T3 (es) | 2006-03-23 | 2012-10-16 | Novartis Ag | Compuestos inmunopotenciadores |
| ES2536426T3 (es) * | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| JP5275983B2 (ja) * | 2006-06-12 | 2013-08-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| PT2032163E (pt) * | 2006-06-15 | 2013-04-11 | Novartis Ag | Regime em multidoses de vacinação de influenza poupador de adjuvante |
| WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
| AU2007269557B2 (en) | 2006-07-07 | 2013-11-07 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| GB0616306D0 (en) | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
| WO2008028957A2 (en) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine |
| RU2460539C2 (ru) | 2006-10-10 | 2012-09-10 | Вайет | СПОСОБ ОЧИСТКИ ПОЛИСАХАРИДОВ Streptococcus pneumoniae 3 ТИПА (ВАРИАНТЫ) |
| KR101151202B1 (ko) | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 수중유 에멀젼 애주번트를 포함하는 백신 |
| WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
| PT2125792E (pt) | 2007-02-19 | 2011-03-01 | Glaxosmithkline Llc | Derivados de purina como imunomoduladores |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| JP5400763B2 (ja) | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
| ES2359123T3 (es) * | 2007-08-03 | 2011-05-18 | Pfizer Limited | Imidazopiridinonas. |
| SI2200642T1 (sl) | 2007-10-19 | 2012-06-29 | Novartis Ag | Formulacije meningokoknega cepiva |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| EP2235532B1 (en) | 2007-12-24 | 2013-04-24 | Novartis AG | Assays for adsorbed influenza vaccines |
| SI2268618T1 (sl) | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| US9073913B2 (en) | 2008-03-24 | 2015-07-07 | 4Sc Ag | Substituted imidazoquinolines |
| EP2303236A4 (en) | 2008-07-01 | 2012-09-26 | Univ Emory | SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS |
| JP2011528222A (ja) * | 2008-07-18 | 2011-11-17 | アイディー バイオメディカル コーポレイション オブ ケベック | キメラ呼吸器合胞体ウイルスポリペプチド抗原 |
| DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
| TWM352127U (en) | 2008-08-29 | 2009-03-01 | Bestac Advanced Material Co Ltd | Polishing pad |
| EA026557B1 (ru) | 2008-12-09 | 2017-04-28 | Джилид Сайэнс, Инк. | Промежуточные соединения для получения модуляторов толл-подобных рецепторов |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| SG2014014385A (en) * | 2009-02-17 | 2014-04-28 | Glaxosmithkline Biolog Sa | Inactivated dengue virus vaccine with aluminium-free adjuvant |
| CA3154626A1 (en) | 2009-04-14 | 2010-10-21 | Glaxosmithkline Biologicals S.A. | Compositions for immunising against staphylococcus aureus |
| US20120052088A1 (en) * | 2009-04-30 | 2012-03-01 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| EP2433645B1 (en) * | 2009-05-01 | 2016-06-15 | Osaka University | Novel malaria vaccine |
| CA2764022A1 (en) | 2009-06-01 | 2010-12-09 | Novartis Ag | Combinations of pneumococcal rrgb clades |
| CN102762226A (zh) | 2009-06-10 | 2012-10-31 | 诺华有限公司 | 含苯并萘啶的疫苗 |
| AU2010288240B2 (en) | 2009-08-27 | 2014-03-27 | Novartis Ag | Hybrid polypeptides including meningococcal fHBP sequences |
| MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| AU2010314861A1 (en) | 2009-11-09 | 2012-07-05 | National Jewish Health | Vaccine composition |
| US8808703B2 (en) | 2010-03-23 | 2014-08-19 | Tom Yao-Hsiang Wu | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc |
| WO2011130379A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| CN105999275A (zh) * | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| US9618508B2 (en) | 2010-12-14 | 2017-04-11 | Glaxosmithkline Biologicals Sa | Flow cytometry analysis of materials adsorbed to metal salts |
| ES2681698T3 (es) | 2011-03-02 | 2018-09-14 | Glaxosmithkline Biologicals Sa | Vacunas de combinación con menores dosis de antígeno y/o adyuvante |
| US20140363461A1 (en) | 2011-09-01 | 2014-12-11 | Fabio Bagnoli | Adjuvanted formulations of staphylococcus aureus antigens |
| CA2865759C (en) | 2012-03-07 | 2020-07-21 | Novartis Ag | Immunologically useful arginine salts |
| CN104519910B (zh) | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
| CN104582726A (zh) | 2012-03-07 | 2015-04-29 | 诺华股份有限公司 | 狂犬病病毒免疫原的含佐剂制剂 |
| AU2013229432A1 (en) * | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| US9526776B2 (en) | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
| CA2888721A1 (en) | 2012-10-25 | 2014-05-01 | Glaxosmithkline Biologicals Sa | Nicotinamide as adjuvant |
-
2012
- 2012-03-02 ES ES12709382.1T patent/ES2681698T3/es active Active
- 2012-03-02 US US14/002,700 patent/US20140112950A1/en not_active Abandoned
- 2012-03-02 WO PCT/IB2012/050989 patent/WO2012117377A1/en not_active Ceased
- 2012-03-02 KR KR1020137026063A patent/KR20140026392A/ko not_active Withdrawn
- 2012-03-02 RU RU2013144207/15A patent/RU2013144207A/ru not_active Application Discontinuation
- 2012-03-02 JP JP2013555984A patent/JP6191082B2/ja not_active Expired - Fee Related
- 2012-03-02 AU AU2012222883A patent/AU2012222883A1/en not_active Abandoned
- 2012-03-02 CA CA2828844A patent/CA2828844C/en active Active
- 2012-03-02 TR TR2018/11280T patent/TR201811280T4/tr unknown
- 2012-03-02 CN CN201280021519.7A patent/CN103533954B/zh active Active
- 2012-03-02 EP EP12709382.1A patent/EP2680885B8/en not_active Revoked
- 2012-03-02 BR BR112013022397A patent/BR112013022397A2/pt not_active Application Discontinuation
-
2017
- 2017-05-17 JP JP2017097780A patent/JP2017197546A/ja active Pending
-
2018
- 2018-02-02 US US15/887,203 patent/US10603369B2/en active Active
- 2018-05-09 US US15/975,388 patent/US20180256695A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012222883A1 (en) | 2013-10-17 |
| CA2828844C (en) | 2020-07-14 |
| WO2012117377A1 (en) | 2012-09-07 |
| EP2680885B8 (en) | 2018-07-25 |
| CA2828844A1 (en) | 2012-09-07 |
| JP6191082B2 (ja) | 2017-09-06 |
| US10603369B2 (en) | 2020-03-31 |
| US20180169204A1 (en) | 2018-06-21 |
| BR112013022397A2 (pt) | 2017-09-26 |
| JP2014506916A (ja) | 2014-03-20 |
| CN103533954B (zh) | 2015-09-09 |
| CN103533954A (zh) | 2014-01-22 |
| TR201811280T4 (tr) | 2018-08-27 |
| EP2680885A1 (en) | 2014-01-08 |
| US20180256695A1 (en) | 2018-09-13 |
| US20140112950A1 (en) | 2014-04-24 |
| ES2681698T3 (es) | 2018-09-14 |
| JP2017197546A (ja) | 2017-11-02 |
| KR20140026392A (ko) | 2014-03-05 |
| EP2680885B1 (en) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013144207A (ru) | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта | |
| JP2014506916A5 (enExample) | ||
| RU2008112289A (ru) | Множественная вакцинация, включающая менингококки серогруппы с | |
| RU2009149359A (ru) | Состав вакцин против менингита | |
| Knuf et al. | Comparative effects of carrier proteins on vaccine-induced immune response | |
| JP5281224B2 (ja) | ワクチン組成物 | |
| RU2014140521A (ru) | Адъювантные составы бустерных вакцин | |
| RU2006142156A (ru) | Объединенные менингококковые конъюгаты с общим белком-носителем | |
| DK2200642T3 (da) | Meningococvaccinepræparater | |
| JP2015028032A (ja) | ワクチン | |
| SK288007B6 (sk) | Multivalent vaccine composition, process for its producing, and its use | |
| HRP20120102T1 (hr) | Imunogeni pripravak | |
| RU2015106745A (ru) | Иммуногенные композиции | |
| RU2007130774A (ru) | Вакцинация менингококковыми конъюгатами | |
| ATE480257T1 (de) | Kombinationsvakzine mit niedriger dosis eines hib-konjugats | |
| JP2015509963A5 (enExample) | ||
| RU2007138492A (ru) | Комбинированные вакцины с антигеном коклюша цельных клеток | |
| US20150320852A1 (en) | Conjugates for protecting against diphtheria and/or tetanus | |
| ES2365557T5 (es) | Vacunas de combinación de Poliovirus inactivado | |
| JPWO2020117618A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161213 |